Product image of Linagliptin 1a Pharma (Linagliptin) supplied by GNH India

Linagliptin 1a Pharma

Active Ingredient:
Linagliptin
Origin:
EU

Linagliptin 1a Pharma (Linagliptin)

Linagliptin, the active ingredient in Linagliptin 1a Pharma, is a Dipeptidyl peptidase‑4 (DPP‑4) inhibitor presented as an oral tablet for oral use. It is indicated for the management of type 2 diabetes mellitus in adults, helping to improve glycaemic control when used with diet and exercise.
GNH India supplies Linagliptin 1a Pharma as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Manufacturer / TM Owner

1 A Pharma Gmbh

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

Linagliptin is a DPP‑4 inhibitor used in the treatment of type 2 diabetes mellitus, acting on the incretin pathway to regulate blood glucose.

  • Type 2 diabetes mellitus (monotherapy): lowers fasting and post‑prandial glucose levels.
  • Type 2 diabetes mellitus (combined with metformin): enhances overall glycaemic control.
  • Type 2 diabetes mellitus (adjunct to lifestyle modification): supports blood‑sugar management alongside diet and exercise.

How It Works

  • Linagliptin selectively inhibits the enzyme dipeptidyl peptidase‑4 (DPP‑4), preventing the breakdown of endogenous incretin hormones such as GLP‑1 and GIP. Elevated incretin levels increase glucose‑dependent insulin secretion from pancreatic β‑cells and suppress glucagon release from α‑cells, resulting in reduced hepatic glucose production and improved post‑prandial glucose control.

Side Effects

Common Side Effects

  • Nasopharyngitis: mild inflammation of the nose and throat.
  • Headache: transient mild to moderate pain.
  • Gastrointestinal upset: includes nausea, abdominal discomfort, or diarrhoea.
  • Dizziness: occasional light‑headed sensation.
  • Back pain: intermittent musculoskeletal discomfort.
  • Arthralgia: joint pain without swelling.

Serious or Rare Side Effects

  • Pancreatitis: severe abdominal pain with elevated enzymes.
  • Severe hypersensitivity: rash, angioedema, or anaphylaxis.
  • Hepatic injury: marked elevation of liver enzymes.
  • Bullous skin reactions: Stevens‑Johnson syndrome or toxic epidermal necrolysis.
  • Severe hypoglycaemia: when combined with insulin or sulfonylureas.
  • Angioedema: swelling of face, lips, or airway.

Precautions & Warnings

Linagliptin should be prescribed after evaluating patient‑specific factors and monitoring for adverse events.

  • Renal impairment: assess kidney function; dose adjustment may be required.
  • Hepatic disease: monitor liver enzymes regularly.
  • Elderly patients: watch for hypoglycaemia when used with insulin or sulfonylureas.
  • Pregnancy and lactation: use only if potential benefit justifies potential risk.
  • Drug interactions: review concomitant medications for additive effects.
  • Store at room temperature: keep in original packaging, protect from moisture and direct sunlight.

Avoid Interactions

Linagliptin may interact with several drug classes, requiring clinical vigilance.

Major Interactions (Avoid)

  • Insulin: increased risk of hypoglycaemia.
  • Sulfonylureas: additive hypoglycaemic effect.
  • Strong CYP3A4 inhibitors: may raise linagliptin plasma levels.

Moderate Interactions (Monitor Closely)

  • ACE inhibitors: monitor renal function and electrolytes.
  • Diuretics: watch for changes in fluid balance.
  • Warfarin: periodic INR checks recommended.

Frequently Asked Questions

Linagliptin 1a Pharma contains the DPP‑4 inhibitor linagliptin and is used to improve blood‑glucose control in adults with type 2 diabetes mellitus, typically as part of a regimen that includes diet, exercise, and possibly other antidiabetic agents.

Linagliptin blocks the dipeptidyl peptidase‑4 enzyme, which normally degrades incretin hormones. By preserving incretins, it enhances glucose‑dependent insulin release, reduces glucagon secretion, and lowers hepatic glucose output, thereby helping to regulate blood sugar levels.

The specific dose and dosing schedule are determined by the prescribing healthcare professional based on the individual’s clinical condition, renal function, and concomitant therapies. Patients should follow the prescriber’s instructions exactly.

Safety data for linagliptin in pregnancy and lactation are limited. It should only be used if the potential benefit to the mother outweighs any possible risk to the fetus or infant, and this decision must be made by a qualified clinician.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details, and any necessary import documentation.

Linagliptin shares the same mechanism of action as other DPP‑4 inhibitors but has a distinct pharmacokinetic profile, including a long half‑life and minimal renal excretion, which may reduce the need for dose adjustments in patients with renal impairment.

Store the tablets at room temperature, below 25 °C, in the original blister pack or container. Keep them away from moisture, heat, and direct sunlight to maintain product stability.

Linagliptin 1a Pharma is taken orally, usually once daily, with or without food. The tablet should be swallowed whole with water and not chewed or crushed.

Serious risks include pancreatitis, severe hypersensitivity reactions such as angioedema or Stevens‑Johnson syndrome, and hepatic injury. Patients should seek immediate medical attention if they experience persistent abdominal pain, rash, swelling, or jaundice.

Linagliptin is contraindicated in patients with a known hypersensitivity to linagliptin or any component of the formulation. Caution is also advised for individuals with severe hepatic impairment or a history of pancreatitis.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Related Products

Other formulations containing Linagliptin

A

A
A

A
A

A
A

A

Browse all products →

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Regulatory recognitions

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.

SGS GSDP Certification

GSDP Compliant from SGS

URS ISO 9001

URS ISO 9001 Certification

FDA Maharashtra

Licensed by FDA Maharashtra

IEC License DGFT

IEC License issued by DGFT